Citations

Clear

3138 citation(s) found for "Smith, AM".

Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients
Hansrivijit, Panupong , Kovvuru, Karthik , Kanduri, Swetha Rani , Cheungpasitporn, Wisit , Pivovarova, Aleksandra I. , Smith, Justin R. , Hansrivijit, Panupong , Pivovarova, Aleksandra , Cheungpasitporn, Wisit , Thongprayoon, Charat

Mayo Clinic

Journal of Clinical Medicine | July 14, 2020 | Volume: 9 | Issue: 7 | Pages: 2193

10.3390/jcm9072193 | PMID 32664531 Get It

Tacrolimus is a first-line calcineurin inhibitor (CNI) and an integral part of the immunosuppressive strategy in solid organ transplantation. Being a dose-critical drug, tacrolimus has a narrow therapeutic index that necessitates periodic monitoring to maintain the drug’s efficacy and reduce the consequences of overexposure. Tacrolimus is characterized by substantial intra- and inter-individual pharmacokinetic variability. At steady state, the tacrolimus blood concentration to daily dose ratio (C/D ratio) has been described as a surrogate for the estimation of the individual metabolism rate, where a low C/D ratio reflects a higher rate of metabolism. Fast tacrolimus metabolism (low C/D ratio) is associated with the risk of poor outcomes after transplantation, including reduced allograft function and survival, higher allograft rejection, CNI nephrotoxicity, a faster decline in kidney function, reduced death-censored graft survival (DCGS), post-transplant lymphoproliferative disorders, dyslipidemia, hypertension, and cardiovascular events. In this article, we discuss the potential role of the C/D ratio in a noninvasive monitoring strategy for identifying patients at risk for potential adverse events post-transplant.
Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001
Persky, Daniel O. , Li, Hongli , Stephens, Deborah M. , Park, Steven I., Bartlett, Nancy L. , Swinnen, Lode J., Winegarden, Jerome D., FitzGerald, Thomas J. , Leonard, John P. , Song, Joo Y. , Fisher, Richard I., Smith, Sonali M. , Miller, Thomas P. , Friedberg, Jonathan W. , Park, Steven , Song, Joo Y , Bartlett, Nancy L , FitzGerald, Thomas J , Park, Steven I , Stephens, Deborah M , Barr, Paul M. , Constine, Louis S , Kahl, Brad S. , LeBlanc, Michael , Rimsza, Lisa M.

Mayo Clinic

Journal of Clinical Oncology | July 13, 2020 | Volume: 38 | Issue: 26 | Pages: 3003-3011

10.1200/jco.20.00999 | PMID 32658627 Get It

PURPOSEDiffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in 25% to 30% of patients, with better overall survival (OS) than that for advanced-stage disease but with continuous relapse regardless of treatment approach. The preferred treatment is abbreviated rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and radiation therapy. On the basis of promising results of positron emission tomography (PET)–directed treatment approaches, we designed a National Clinical Trials Network (NCTN) study to improve outcomes and decrease toxicity.METHODSPatients with nonbulky (< 10 cm) stage I/II untreated DLBCL received 3 cycles of standard R-CHOP therapy and underwent a centrally reviewed interim PET/computed tomography scan (iPET). Those with a negative iPET proceeded with 1 additional cycle of R-CHOP, whereas those with a positive iPET received involved field radiation therapy followed by ibritumomab tiuxetan radioimmunotherapy.RESULTSOf 158 patients enrolled, 132 were eligible and 128 underwent iPET, which was positive in 14 (11%) of the patients. With a median follow-up of 4.92 years (range, 1.1-7.7 years), only 6 patients progressed and 3 died as a result of lymphoma. Eleven patients died as a result of nonlymphoma causes at a median age of 80 years. The 5-year progression-free survival estimate was 87% (95% CI, 79% to 92%) and the OS estimate was 89% (95% CI, 82% to 94%), with iPET-positive and iPET-negative patients having similar outcomes.CONCLUSIONTo our knowledge, S1001 is the largest prospective study in the United States of limited-stage DLBCL in the rituximab era, with the best NCTN results in this disease subset. With PET-directed therapy, 89% of the patients with a negative iPET received R-CHOP × 4, and only 11% had a positive iPET and required radiation, with both groups having excellent outcomes. The trial establishes R-CHOP × 4 alone as the new standard approach to limited-stage disease for the absolute majority of patients.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
Shah, Nina , Aiello, Jack, Avigan, David , Borrello, Ivan , Chari, Ajai , Cohen, Adam D. , Ganapathi, Karthik A. , Gray, Lissa , Green, Damian, Krishnan, Amrita , Lin, Yi , Manasanch, Elisabet E. , Munshi, Nikhil C. , Rapoport, Aaron P. , Smith, Eric L. , Vij, Ravi , Dhodapkar, Madhav V. , Cohen, Adam D , Chari, Ajai , Lin, Yi , Berdeja, Jesús G. , Green, Damian J , Nooka, Ajay K.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 13, 2020 | Volume: 8 | Issue: 2 | Pages: e000734

10.1136/jitc-2020-000734 | PMID 32661116 Get It

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor (CAR) T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.
Healthy eating in a Boys & Girls Club afterschool programme: Barriers, facilitators and opportunities
Brockman, Tabetha A. , Sim, Leslie , Biggs, Bridget K. , Bronars, Carrie, Tolleson, Ellen, Asiedu, Gladys B. , Hanza, Marcelo M., Olson, Molly A, Slowiak, Kathleen A, Weis, Jennifer A., Clark, Matthew M. , Millerbernd, Jodi, Sia, Irene G. , Biggs, Bridget K , Sia, Irene G , Brockman, Tabetha A , Meiers, Sonja J. , Ridgeway, Jennifer L. , Patten, Christi A. , Wieland, Mark L.

Mayo Clinic

Health Education Journal | July 10, 2020 | Volume: 79 | Issue: 8 | Pages: 914-931

10.1177/0017896920936722 Get It

Objective: To determine intervention needs and to gather stakeholder input regarding healthy eating promotion for youth members served at a Boys & Girls Club in Rochester, Minnesota. Design: Mixed-methods design informed by community-based participatory research principles. Setting and Method: Young people completed a dietary habits questionnaire and height and weight measure-ments. Focus groups gathered stakeholder – Boys & Girls Club members, staff, caregivers – perspectives on opportunities to improve children’s healthy eating through the club setting. Content analysis identified major themes in informants’ accounts. Results: Participants identified individual and environmental barriers to healthy eating and opportunities to reduce barriers at this Boys & Girls Club site. Few children met basic nutritional guidelines related to fruit, vegetable, milk and water consumption, and limiting consumption of sugar-sweetened beverages, and nearly half were overweight/obese. Stakeholders expressed interest in healthy eating promotion and identified multiple individual-level, interpersonal and environmental opportunities to promote healthier eating through the Boys & Girls Club site. Conclusion: Findings build on a growing literature indicating afterschool programmes are uniquely positioned to address health disparities related to paediatric nutrition and obesity, and can be used to inform the design of a multi-layered intervention to address the complexities influencing dietary quality and obesity among diverse and underserved youth.
COVID‐19 and Headache Medicine: A Narrative Review of Non‐Steroidal Anti‐Inflammatory Drug (NSAID) and Corticosteroid Use
Arca, Karissa N., Chiang, Chia‐Chun , Starling, Amaal J. , Robertson, Carrie E. , Schwedt, Todd J. , Kissoon, Narayan , Garza, Ivan , Rozen, Todd D. , Whealy, Mark , VanderPluym, Juliana H. , Chiang, Chia-Chun , Starling, Amaal J , Halker Singh, Rashmi B, Schwedt, Todd J , Kissoon, Narayan R , Garza, Ivan , Rozen, Todd D , Boes, Christoper J , Whealy, Mark A , Robertson, Carrie E , VanderPluym, Juliana , Smith, Jonathan H. , Singh, Rashmi B. Halker , Boes, Christopher J.

Mayo Clinic

Headache: The Journal of Head and Face Pain | July 10, 2020 | Volume: 60 | Issue: 8 | Pages: 1558-1568

10.1111/head.13903 | PMID 32648592 Get It

Objective To summarize the current literature on non‐steroidal anti‐inflammatory drug and corticosteroid use during the coronavirus disease 2019 (COVID‐19) pandemic, recognizing that these are commonly used treatments in the field of headache medicine. Background The use of non‐steroidal anti‐inflammatory drugs and corticosteroids in patients during the COVID‐19 pandemic has been a controversial topic within the medical community and international and national health organizations. Lay press and social media outlets have circulated opinions on this topic despite the fact that the evidence for or against the use of these medications is sparse. In the field of headache medicine, these medications are used commonly and both patients and clinicians may have questions or hesitations pertaining to their use during the COVID‐19 pandemic. Methods A detailed search of the scientific and popular literature was performed. Results There is limited literature pertaining to the safety of non‐steroidal anti‐inflammatory drugs and corticosteroids during the COVID‐19 pandemic. To date, there are no clear scientific data that preclude the use of non‐steroidal anti‐inflammatory drugs in the general population who may acquire COVID‐19 or in those acutely infected with the virus. Several health organizations have concluded that treatment with corticosteroids during active infection should be avoided due to concerns of prolonged viral shedding in the respiratory tract and the lack of survival benefit based on the data from past coronaviruses and influenza virus; specific exceptions exist including treatment for underlying asthma or chronic obstructive pulmonary disease, septic shock, and acute respiratory distress syndrome. Conclusion Scientific information regarding the COVID‐19 pandemic is constantly evolving, and limited or contradictory information can lead to confusion for both patients and clinicians. It is recommended that prior to prescribing non‐steroidal anti‐inflammatory drugs and steroids for the treatment of headache, clinicians have open discussions with their patients about the potential risks and benefits of using these medications during the COVID‐19 pandemic. This manuscript summarizes the currently available evidence and understanding about these risks and benefits to help clinicians navigate such discussions.
Bilateral Oophorectomy as a Risk Factor for the Development of Obstructive Lung Disease
Smith, Carin, Rocca, Walter A. , Scrodin, M. Dulohery, Nguyen, Thanh Thanh L. , Vassallo, Robert

Mayo Clinic

D107. ENVIRONMENTAL EXPOSURES AND COPD | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A7839-A7839

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7839 Get It

Pulmonary Manifestations in a Patient with Chai Disease
Smith, Ryan J. , Mertz, L. E., Teaford, Harry G., Cartin‐Ceba, Rodrigo

Mayo Clinic

A34. AUTO IMMUNE LUNG DISEASE: CASE REPORTS | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A1382-A1382

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1382 Get It

Pulmonary Surface Index: A Quantitative CT Biomarker for Idiopathic Pulmonary Fibrosis
Kulkarni, Tejaswini , Elkassem, Asser Abou , Mresh, Rafah, Farag, Amany , Sonavane, Sushilkumar K. , Smith, A. Blair , Farag, A.

Mayo Clinic

A23. ILD PROGNOSIS AND BIOMARKERS I | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A1083-A1083

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1083 Get It

Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go
Đačić, Sanja , Attanoos, Richard , Borczuk, Alain , Colby, Thomas V. , Jones, Kirk D. , Leslie, Kevin O., Mahar, Annabelle , Larsen, Brandon T. , Fukuoka, Jun, Roden, Anja C. , Sholl, Lynette M. , Tazelaar, Henry D. , Beasley, Mary Beth , Smith, Maxwell L. , Hariri, Lida P. , Mino-Kenudson, Mari A. , Cooper, Wendy A , Tazelaar, Henry D. , Churg, Andrew

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 2, 2020 | Volume: 144 | Issue: 12 | Pages: 1477-1489

10.5858/arpa.2020-0052-ra | PMID 32614648 Get It

Context.— Accurate diagnosis of idiopathic pulmonary fibrosis (IPF) requires multidisciplinary diagnosis that includes clinical, radiologic, and often pathologic assessment. In 2018, the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and the Latin American Thoracic Society (ATS/ERS/JRS/ALAT) and the Fleischner Society each published guidelines for the diagnosis of IPF, which include criteria for 4 categories of confidence of a histologic usual interstitial pneumonia (UIP) pattern. Objective.— To (1) identify the role of the guidelines in pathologic assessment of UIP; (2) analyze the 4 guideline categories, including potential areas of difficulty; and (3) determine steps the Pulmonary Pathology Society and the greater pulmonary pathology community can take to improve current guideline criteria and histopathologic diagnosis of interstitial lung disease. Data Sources.— Data were derived from the guidelines, published literature, and clinical experience. Conclusions.— Both guidelines provide pathologists with a tool to relay to the clinician the likelihood that a biopsy represents UIP, and serve as an adjunct, not a replacement, for traditional histologic diagnosis. There are multiple challenges with implementing the guidelines, including (1) lack of clarity on the quantity and quality of histologic findings required, (2) lack of recognition that histologic features cannot be assessed independently, and (3) lack of guidance on how pathologists should incorporate clinical and radiographic information. Current criteria for “probable UIP” and “indeterminate for UIP” hinder accurate reflection of the likelihood of IPF. These challenges highlight the need for further morphologic-based investigations in the field of pulmonary pathology.
Reducing Opioid Exposure in a Level IV Neonatal Intensive Care Unit
Stetson, Raymond C. , Smith, Brandi, Sanders, Nicole, Misgen, Megan A., Ferrie, LaRae J., Schuning, Virginia S., Schuh, Allison R., Fang, Jennifer L. , Smith, Brandi N, Sanders, Nicole L, Brumbaugh, Jane E. , Misgen, Megan M.

Mayo Clinic

Pediatric Quality & Safety | July 1, 2020 | Volume: 5 | Issue: 4 | Pages: e312

10.1097/pq9.0000000000000312 | PMID 32766487 Get It

Introduction: Infants in neonatal intensive care units require painful and noxious stimuli as part of their care. Judicious use of analgesic medications, including opioids, is necessary. However, these medications have long- and short-term side effects, including potential neurotoxicity. This quality improvement project’s primary aim was to decrease opioid exposure by 33% in the first 14 days of life for infants less than 1,250 g at birth within 12 months. Methods: A multidisciplinary care team used Define, Measure, Analyze, Improve, Control methodology to identify root causes of the quality gap including: (1) inconsistent reporting of objective pain scales; (2) variable provider prescribing patterns; and (3) variable provider bedside assessment of pain. These root causes were addressed by two interventions: (1) standardized reporting of the premature infant pain profile scores and (2) implementation of an analgesia management pathway. Results: Mean opioid exposure, measured in morphine equivalents, in infants less than 1,250 g at birth during their first 14 days of life decreased from 0.64 mg/kg/d (95% confidence interval 0.41–0.87) at baseline to 0.08 mg/kg/d (95% confidence interval 0.03–0.13) during the postintervention period (P < 0.001). There was no statistical difference in rates of days to full feedings, unintentional extubations, or central line removals between epochs. Conclusions: Following the implementation of consistent pain score reporting and an analgesia management pathway, opioid exposure in the first 14 days of life for infants less than 1,250 g was significantly reduced by 88%, exceeding the project aim.